Clinical implications of dopamine research in schizophrenia

Current Medical Research and Opinion

Volumn 18, Issue SUPPL. 3, 2002, Pages s3-s7

  Pani, L ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

dopamine receptors; frontal cortex; limbic system; negative symptoms; positive symptoms; presynaptic; schizophrenia

Indexed keywords

DOPAMINE RECEPTOR; DRUG DERIVATIVE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; RESEARCH; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; HUMANS; RECEPTORS, DOPAMINE; RESEARCH; SCHIZOPHRENIA; SULPIRIDE;

EID: 0036370924     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/030079902125001056     Document Type: Article

References (15)

1. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966;18:925-64
2. Carlsson A. Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 1978;135:164-73
3. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacol-ogy 1996;124:2-34
4. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280:83-97
5. Carlsson A. The dopamine theory revisited. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford: Blackwell Science, 1995:379-400
6. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-86
7. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96
8. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 1997;11: 123-31
9. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic patients. Proc Natl Acad Sci USA 1996;93:9235-40
10. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57(Suppl 11):4-11
11. 3 dopamine receptor antagonistic activity and limbic selectivity. J Pharmacol Exp Ther 1997;280:73-82
12. 3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons. J Pharmacol Exp Ther 1998;287:51-7
13. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, gluta-mate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001;41:237-60
14. Cudennec A, Fage D, Bénavidès J, Scatton B. Effects of amisulpride, an atypical antipsychotic which blocks presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat. Brain Res 1997;768: 257-65
15. Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Pharmacology 1997;12(Suppl 2):S29-S36